We held our latest webinar on September 11th, called Myeloma and infection: clinical and lived perspectives for myeloma patients, carers and advocates. Jackie Quinn, Myeloma Clinical Nurse Specialist, Belfast Trust presented on how myeloma and treatments increase infection risk, covering immunisations, bispecific antibody risks, and preventive medications. Mimi Quinn, myeloma patient from Ireland shared her personal…
Myeloma is a form of blood cancer. At diagnosis, and at each relapse, myeloma patients are confronted with complex treatment and care decisions that may feel overwhelming. What are my options? What are the side effects? How will it affect my quality of life? The questions you have regarding your care choices are deeply personal…
Myeloma Patients Europe (MPE) will host a webinar on “Myeloma and infection: clinical and lived perspectives” on Thursday, 11th September 2025 from 17:00 – 18:00 CEST. Aimed at myeloma patients, carers and patient advocates, the webinar will feature presentations on infection risk and prevention in myeloma, and a patient’s experiences of infection in myeloma. Jackie Quinn,…
The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are eligible for autologous stem cell transplant. The decision follows an earlier positive recommendation of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP…
Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP – their scientific advisory committee) on 23 May 2025. Marketing authorisation means that…
The European Commission (EC) has approved a new indication for daratumumab (Darzalex®) for the treatment of adult patients with smouldering myeloma (SMM) at high-risk of developing myeloma. This follows a positive recommendation from the Committee for Medicinal Product for Human Use (CHMP) in June 2025. The CHMP is the European Medicines Agency’s (EMA) committee playing…
On July 7th, 2025, new clinical management guidelines for myeloma and smouldering myeloma were published in Nature Reviews Clinical Oncology by myeloma experts. These guidelines are written to guide doctors and healthcare professionals in myeloma and smouldering myeloma diagnosis, treatment and follow-up, based on the most up-to-date scientific knowledge. The last treatment guidelines were published in…
On May 23rd, MPE member organisation, Multiple Myeloma Ireland (MMI) successfully hosted its 2025 Patient and Family Information Day at the Ashling Hotel in Dublin. Multiple Myeloma Ireland is the only charitable organisation in Ireland focused exclusively on supporting patients, families and carers with myeloma and related conditions. As a valued member of Myeloma Patients Europe (MPE), MMI…
